MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- PANACEA BIOTECH - ADCOCK INGRAM (S. Africa)
PANACEA BIOTECH vs ADCOCK INGRAM (S. Africa) - Comparison Results
PANACEA BIOTECH Change
Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 PANACEA BIOTECH  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| PANACEA BIOTECH Mar-19 |
ADCOCK INGRAM Jun-14 |
PANACEA BIOTECH/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 354 | 344 | - | |
| Low | Rs | 138 | 248 | - | |
| Sales per share (Unadj.) | Rs | 74.6 | 102.4 | - | |
| Earnings per share (Unadj.) | Rs | 6.7 | -25.8 | - | |
| Cash flow per share (Unadj.) | Rs | 15.5 | -21.4 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 57.2 | 80.4 | - | |
| Shares outstanding (eoy) | m | 61.25 | 168.78 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 3.3 | 2.9 | 114.0% | |
| Avg P/E ratio | x | 36.8 | -11.5 | -320.6% | |
| P/CF ratio (eoy) | x | 15.9 | -13.9 | -114.5% | |
| Price / Book Value ratio | x | 4.3 | 3.7 | 116.6% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 15,061 | 50,026 | 30.1% | |
| No. of employees | `000 | 2.3 | 4.3 | 53.9% | |
| Total wages/salary | Rs m | 1,471 | 3,140 | 46.8% | |
| Avg. sales/employee | Rs Th | 1,973.6 | 4,027.5 | 49.0% | |
| Avg. wages/employee | Rs Th | 635.6 | 731.4 | 86.9% | |
| Avg. net profit/employee | Rs Th | 176.8 | -1,014.8 | -17.4% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 4,567 | 17,290 | 26.4% | |
| Other income | Rs m | 45 | 121 | 37.0% | |
| Total revenues | Rs m | 4,612 | 17,411 | 26.5% | |
| Gross profit | Rs m | 2,030 | -2,996 | -67.7% | |
| Depreciation | Rs m | 540 | 746 | 72.4% | |
| Interest | Rs m | 1,048 | 468 | 223.8% | |
| Profit before tax | Rs m | 486 | -4,090 | -11.9% | |
| Minority Interest | Rs m | 0 | -11 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 77 | 256 | 30.2% | |
| Profit after tax | Rs m | 409 | -4,357 | -9.4% | |
| Gross profit margin | % | 44.4 | -17.3 | -256.5% | |
| Effective tax rate | % | 15.9 | -6.2 | -253.8% | |
| Net profit margin | % | 9.0 | -25.2 | -35.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 2,415 | 12,664 | 19.1% | |
| Current liabilities | Rs m | 9,077 | 7,125 | 127.4% | |
| Net working cap to sales | % | -145.9 | 32.0 | -455.4% | |
| Current ratio | x | 0.3 | 1.8 | 15.0% | |
| Inventory Days | Days | 65 | 111 | 58.7% | |
| Debtors Days | Days | 71 | 124 | 57.2% | |
| Net fixed assets | Rs m | 8,333 | 7,382 | 112.9% | |
| Share capital | Rs m | 61 | 80 | 76.4% | |
| Net worth | Rs m | 3,504 | 13,571 | 25.8% | |
| Long term debt | Rs m | 461 | 4,769 | 9.7% | |
| Total assets | Rs m | 13,755 | 25,636 | 53.7% | |
| Interest coverage | x | 1.5 | -7.7 | -18.9% | |
| Debt to equity ratio | x | 0.1 | 0.4 | 37.5% | |
| Sales to assets ratio | x | 0.3 | 0.7 | 49.2% | |
| Return on assets | % | 10.6 | -15.2 | -69.9% | |
| Return on equity | % | 11.7 | -32.1 | -36.4% | |
| Return on capital | % | 38.7 | -19.8 | -195.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,049 | 1,476 | 71.1% | |
| From Investments | Rs m | -54 | -453 | 11.8% | |
| From Financial Activity | Rs m | -1,011 | 4,328 | -23.4% | |
| Net Cashflow | Rs m | -20 | 5,351 | -0.4% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.75 Rs / ZAR
Compare PANACEA BIOTECH With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare PANACEA BIOTECH With: UNICHEM LAB PFIZER ABBOTT INDIA STERLING BIOTECH AJANTA PHARMA
Today's Market
A Time Correction in the Nifty(Momentum Moves)
The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.
Related Views On News
PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)
Mar 27, 2019 | Updated on Mar 27, 2019Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)
Feb 25, 2021In this video, I'll show you how to get started on the path to daily trading profits.
The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)
Feb 23, 2021An Indian company founded three decades ago in a garage caught my attention...
Gold 65,000 and Silver 84,000 in 2022
Feb 26, 2021In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More
